company background image
ERNA logo

Eterna Therapeutics NasdaqCM:ERNA Stock Report

Last Price

US$0.25

Market Cap

US$12.8m

7D

-4.9%

1Y

-87.4%

Updated

24 Dec, 2024

Data

Company Financials

Eterna Therapeutics Inc.

NasdaqCM:ERNA Stock Report

Market Cap: US$12.8m

ERNA Stock Overview

A life science company, provides mRNA cell engineering technologies. More details

ERNA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Eterna Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eterna Therapeutics
Historical stock prices
Current Share PriceUS$0.25
52 Week HighUS$2.63
52 Week LowUS$0.22
Beta7.21
1 Month Change-52.12%
3 Month Change-76.03%
1 Year Change-87.36%
3 Year Change-99.73%
5 Year Changen/a
Change since IPO-99.74%

Recent News & Updates

Recent updates

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Oct 11

Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

Jul 26

Shareholder Returns

ERNAUS BiotechsUS Market
7D-4.9%-3.3%-0.4%
1Y-87.4%-2.7%24.8%

Return vs Industry: ERNA underperformed the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: ERNA underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is ERNA's price volatile compared to industry and market?
ERNA volatility
ERNA Average Weekly Movement17.4%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: ERNA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ERNA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20188Sanjeev Luthereternatx.com

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.

Eterna Therapeutics Inc. Fundamentals Summary

How do Eterna Therapeutics's earnings and revenue compare to its market cap?
ERNA fundamental statistics
Market capUS$12.79m
Earnings (TTM)-US$44.95m
Revenue (TTM)US$598.00k

21.4x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERNA income statement (TTM)
RevenueUS$598.00k
Cost of RevenueUS$162.00k
Gross ProfitUS$436.00k
Other ExpensesUS$45.39m
Earnings-US$44.95m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.87
Gross Margin72.91%
Net Profit Margin-7,516.56%
Debt/Equity Ratio-81.4%

How did ERNA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:17
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eterna Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Jason McCarthyMaxim Group